Faculty Collaboration Database

Linezolid for the treatment of drug-resistant infections. Expert Rev Anti Infect Ther 2008 Dec;6(6):825-48

Date

12/05/2008

Pubmed ID

19053895

DOI

10.1586/14787210.6.6.825

Scopus ID

2-s2.0-59449100218 (requires institutional sign-in at Scopus site)   31 Citations

Abstract

Multidrug-resistant pathogens have become increasingly common in contemporary healthcare. Specific to Gram-positive pathogens, methicillin-resistant Staphylococcus aureus (MRSA) is of particular concern, as it has been associated with increased hospital length of stay, higher healthcare expenditures and poorer outcomes. To date, linezolid is the first and only oxazolidinone approved by the US FDA for the treatment of infections caused by Gram-positive pathogens, including MRSA. This article will serve as a comprehensive review of linezolid, including an overview of the current market and its in vitro activity, with an in-depth review of its pharmacokinetic and pharmacodynamic profile. Emphasis will be placed on clinical data for the drug, both on- and off-label. The article will conclude with a brief overview of linezolid's pharmacoeconomic implications and safety profile, followed by a commentary and 5-year prospective analysis remarking on the future of the antimicrobial field as it relates to MRSA.

Author List

Herrmann DJ, Peppard WJ, Ledeboer NA, Theesfeld ML, Weigelt JA, Buechel BJ

Authors

Nathan A. Ledeboer PhD Vice Chair, Professor in the Pathology department at Medical College of Wisconsin
William J. Peppard PharmD Trauma/Surgical Critical Care Pharmacist in the Pharmacy department at Froedtert Hospital

MESH terms used to index this publication - Major topics in bold

Acetamides
Anti-Bacterial Agents
Clinical Trials as Topic
Drug Resistance, Multiple, Bacterial
Economics, Pharmaceutical
Gram-Positive Bacterial Infections
Humans
Linezolid
Oxazolidinones